Featured Research

from universities, journals, and other organizations

A boost in microRNA may protect against sepsis and other inflammatory diseases

Date:
May 24, 2012
Source:
Brigham and Women's Hospital
Summary:
Researchers have discovered that a microRNA called miR-181b can reduce the inflammatory response that is responsible for inflammatory diseases.

Acute inflammatory diseases, such as sepsis, as well as chronic inflammatory diseases like diabetes and arthritis, develop as a result of sustained inflammation of the blood vessel wall. Researchers at Brigham and Women's Hospital (BWH) have discovered that a microRNA (small, non-coding RNA molecule) called miR-181b can reduce the inflammatory response that is responsible for such diseases.

The findings, by researchers led by Mark Feinberg, MD from BWH and Harvard Medical School, will pave the way for new targets in the development of anti-inflammatory therapies.

The study is published in the May 24, 2012 online edition of The Journal of Clinical Investigation.

The researchers identified that expression of miR-181b was reduced in both mice and critically ill patients with sepsis. Sepsis is a devastating whole-body inflammatory condition due to infection and is associated with reduced survival.

Each one unit increase in microRNA-181b was associated with a decrease in the odds of having sepsis, suggesting that higher levels of miR-181b may be protective.

The inflammatory response (such as that which causes sepsis) is regulated by a major signaling pathway known as NF-kB. The researchers found that miR-181b is a potent regulator of this pathway within blood vessel walls. miR-181b specifically targets importin-a3, a protein essential in NF-kB signaling.

Overexpression of miR-181b inhibited importin-a3 expression, as well as other molecules involved in the NF-kB signaling pathway; thereby, reducing the inflammation response. The researchers discovered this after giving miR-181b intravenously in mice with sepsis. This led to increased survival and reduced inflammatory damage in the lungs of septic mice.

"We have discovered a microRNA that is important in dampening the inflammatory response and reducing tissue injury by targeting NF-kB in the lining of the blood vessel wall, known as the vascular endothelium," said Feinberg. "The beneficial role of this microRNA in sepsis is likely the tip of the iceberg since excessive inflammation is a pervasive finding in a wide-range of acute and chronic diseases."

In the accompanying commentary, Drs. Jason Fish and Myron Cybulsky from the University of Toronto note that microRNAs, such as miR-181b, may be exciting and attractive targets for future vascular inflammatory disease therapeutics.

Funding for this work came from the National Institutes of Health grants; American Cancer Society grant; and a Watkins Cardiovascular Medicine Discovery award.


Story Source:

The above story is based on materials provided by Brigham and Women's Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jason E. Fish, Myron I. Cybulsky. Taming endothelial activation with a microRNA. Journal of Clinical Investigation, 2012; 122 (6): 1967 DOI: 10.1172/JCI63818

Cite This Page:

Brigham and Women's Hospital. "A boost in microRNA may protect against sepsis and other inflammatory diseases." ScienceDaily. ScienceDaily, 24 May 2012. <www.sciencedaily.com/releases/2012/05/120524123203.htm>.
Brigham and Women's Hospital. (2012, May 24). A boost in microRNA may protect against sepsis and other inflammatory diseases. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2012/05/120524123203.htm
Brigham and Women's Hospital. "A boost in microRNA may protect against sepsis and other inflammatory diseases." ScienceDaily. www.sciencedaily.com/releases/2012/05/120524123203.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins